Lactobacillus plantarum CCFM8610 Alleviates Irritable Bowel Syndrome and Prevents Gut Microbiota Dysbiosis:A Randomized,Double-Blind,Placebo-Controlled,Pilot Clinical Trial

摘要

Irritable bowel syndrome with diarrhea(IBS-D)is chronic intestinal dysfunction with diarrhea and othercomplicated clinical symptoms,and it has a great impact on the daily life and mental state of patients.Some studies have reported that ingestion of probiotics can significantly alleviate a variety of intestinaldiseases.The pupose of this study was to investigate the IBS-D-alleviating effects of a probiotic strain,lactobacillus plantarum(L.plantarum)CCFM8610,with multiple health-promoting effects.The studywas a 12-week,randomized,double-blind,placebo-controlled,pilot clinical trial.Seventy-five patientswere randomly assigned to receive the placebo,oligosaccharides,or L.plantarum CCFM8610(1×10^(10) colony-forming units(CFU)per day),with a 2-week run-in period,an 8-week intervention period,anda 2-week follow-up observation period.The patients'clinical symptoms and quality of life were exam-ined by the IBS symptom severity scale(IBS-SsS)and the IlBS quality of life scale(IBS-QOL).Changes ingut microbiota composition and diversity were measured at the end of the intervention period.The oraladministration of L.plantarum CCFM8610 significantly decreased the IBS-SSS and IBS-QOL scores,reduced IBS-D symptom severity,recovered gut microbiota diversity,decreased the relative abundanceof bloating-related genus Methanobrevibacter,and increased the relative abundance of butyric acid-producing genera,including Anaerostipes,Anaerotruncus,Bifidobacterium,Butyricimonas,andOdoribacter.These findings suggest that ingestion of L.plantarum CCFM8610 can significantly alleviate clinical symptoms and gut microbiota dysbiosis in IBS-D patients.The IBS-D-alleviating effect of L.plan-tarum CCFM8610 may be related to theincrease in the relative abundance of butyric acid-producing genera in the intestine.